AGIO AGIOS PHARMACEUTICALS, INC.

Nasdaq agios.com


$ 40.58 $ 0.35 (0.87 %)    

Tuesday, 14-Oct-2025 13:29:12 EDT
QQQ $ 602.18 $ 6.97 (1.17 %)
DIA $ 464.58 $ 7.57 (1.66 %)
SPY $ 665.34 $ 8.05 (1.22 %)
TLT $ 90.63 $ -0.01 (-0.01 %)
GLD $ 381.68 $ 3.37 (0.89 %)
$ 40.92
$ 39.93
$ 40.57 x 6
$ 40.73 x 16
$ 39.93 - $ 40.64
$ 23.42 - $ 62.58
540,530
na
2.38B
$ 1.15
$ 3.66
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-13-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-16-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

 fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

 saudi-food-and-drug-authority-approves-agios-pyrukynd-for-adults-with-thalassemia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...

 agios-pharmaceuticals-says-it-is-aware-of-the-securities-analyst-report-published-on-august-4-2025-detailing-recent-pyrukynd-data-from-the-us-fda-adverse-event-reporting-system-co-is-committed-to-delivering-safe-effective-treatments-for-patients-with-rare-diseases-and-will-continue-to-follow-our-established-rigorous-pharmacovigilance-processes-separately-on-august-4-2025-the-saudi-food-and-drug-authority-announced-that-it-has-approvedpyrukynd

-SEC Filing

 agios-pharmaceuticals-q2-eps-193-misses-177-estimate-sales-12455m-beat-9537m-estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate ...

 scotiabank-maintains-sector-outperform-on-agios-pharmaceuticals-lowers-price-target-to-65

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Outperform and lowers the price...

 b-of-a-securities-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-51

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target...

 agios-avanmzanite-sign-agreement-for-pan-european-partnership-for-pyrukynd-launch

PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with P...

 agios-pharma-new-data-on-pk-activators-mitapivat-and-tebapivat-to-be-featured-in-oral-and-poster-presentations-during-eha-congress-2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering thera...

 scotiabank-maintains-sector-outperform-on-agios-pharmaceuticals-lowers-price-target-to-71

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Outperform and lowers the price...

 agios-pharmaceuticals-q1-eps-155-beats-180-estimate-sales-873m-miss-964m-estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION